NasdaqGS:ILMNLife Sciences
How Investors May Respond To Illumina (ILMN) Adding Eli Lilly R&D Chief To Its Board
Illumina, Inc. has expanded its Board of Directors from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, as an independent director effective June 16, 2026.
By adding a senior R&D leader with deep experience in drug discovery, clinical development, and precision medicine, Illumina is strengthening board-level expertise closely aligned with its genomics and multiomics...

